This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q3 Earnings
by Zacks Equity Research
Evaluate the expected performance of Humana (HUM) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Molina (MOH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 0.84% and 3.80%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
by Zacks Equity Research
CNC's third-quarter earnings are likely to have been affected by lower premiums and rising medical costs.
Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?
by Kaibalya Pravo Dey
Looking ahead to 2025, UNH projects adjusted earnings to reach around $30 per share at the top end, which falls short of the Zacks Consensus Estimate.
Should You Buy or Hold Molina Healthcare Stock Before Q3 Earnings?
by Zacks Equity Research
MOH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana and Molina Healthcare are part of the Zacks Industry Outlook article.
4 HMO Stocks to Watch Despite Continued Industry Headwinds
by Zacks Equity Research
The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.
UnitedHealth Pre-Q3 Earnings: Golden Opportunity or Fool's Gold?
by Kaibalya Pravo Dey
UNH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Is Humana a Deep Value Stock to Buy?
by David Bartosiak
Humana shares have fallen from over $560 to under $250. Could now be the time to buy?
Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?
by Zacks Equity Research
HUM is facing significant challenges, including membership decline, rising costs and debt burden.
Company News for Oct 3, 2024
by Zacks Equity Research
Companies In The Article Are:CZR,HUM,LW,RPM
Humana and Interwell Health Expand Value-Based Support to Florida
by Zacks Equity Research
HUM and Interwell Health add Florida to their value-based kidney care program in a bid to improve health outcomes.
UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?
by Kaibalya Pravo Dey
With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
by Zacks Equity Research
HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.
Why Is Humana (HUM) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
UnitedHealth (UNH) Rises 15% in 3 Months: Jump in or Wait out?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) expansion into targeted markets, strategic diversification and attractive dividends present significant growth opportunities.
Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
by Zacks Equity Research
Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.
Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Humana (HUM) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 18.17% and 2.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Insights Into Humana (HUM) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Humana (HUM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.